Drug Discovery & Development | US FDA Accepts New Drug Application for Gilead's Idelalisib for the Treatment ... Investor's Business Daily The NDA for iNHL, submitted on September 11, 2013, was supported by a single arm Phase 2 study (Study 101-09) evaluating idelalisib in patients with iNHL that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. FDA Accepts NDA for Gilead Lymphoma Drug |
